Introduction
Nevirapine 1 ( Fig. 1; Boehringer Ingelheim) , a dipyridodiazepinone derivative, was the first non-nucleoside human immunodeficiency virus (HIV) reverse transcriptase (RT) inhibitor licensed in the USA for clinical use in combination with nucleoside analogues in the treatment of AIDS. It was shown by photolabelling experiments with an azidopyrido [2,3-b] [1, 5] benzodiazepinone derivative (Cohen et al., 1991; Wu et al., 1991) and by X-ray structure analysis (crystal structure of HIV-1 RT complexed with nevirapine; Kohlstaedt et aI., 1992; Smerdon et aI., 1994) that 1 interacts at a specific allosteric binding site of the enzyme in the palm domain of the p66 subunit. Despite the efficacy and low toxicity of 1 and other known nonnucleoside RT inhibitors (NNRTIs), there is a continued search for new derivatives owing to the appearance of resistant isolates as a result of HIV-1 RT mutations (Adams & Merluzzi, 1993; De Clercq, 1994a ,b, 1995 Kelly et al., 1995; Proudfoot et al., 1995) .
Recently, we have developed an efficient approach to synthesis of pyridazino [3,4-b] [1,5]benzodiazepin-5-ones (2) (Fig. 1) , structurally closely related to 1. Our synthesis method permits the preparation of compounds of type 2 with a high degree of variability of the substitution pattern in this novel tricyclic system (Heinisch et al., 1997a,b) . So far, we have reported on the chemistry and RT inhibitory activity of compounds 2 with 3-chloro-8nitro, 8-amino, 8-acetylamino and 8-chloro substituents (Heinisch et al., 1997b) . Based on our findings we envisaged additional modifications of the substitution pattern and thus we prepared and investigated 6,1l-dialk.ylated pyridazino [3,4-b] [1,5]benzodiazepin-5-ones bearing a hydrogen atom or a methyl group at position 8. (lH 199.98 MHz) . The centre of the solvent multiplet (CDC1 3 ) was used as an internal standard (chemical shifts in 0 p.p.m.), which was related to TMS with 0 7.26 p.p.m. Elemental analyses were performed by Mag J Theiner (Institute of Physical Chemistry, University of Vienna, Austria). All compounds prepared were analytically pure, the analyses were within ±0.3% of the calculated values. Reactions were monitored by TLC using Polygram SIL G/UV 254 (Macherey-Nagel, Dueren, Germany) plastic-backed plates (0.25 mm layer thickness). Column chromatography was performed using Kieselgel 60 (0.040-0.063 mm; Merck, Darmstadt, Germany). Light petroleum refers to the fraction of b.p. 40-60°C. The yields are not optimized.
Starting materials 3,6-Dichloropyridazine-4-carboxylic acid chloride was prepared from 3,6-dichloropyridazine-4-carboxylic acid with SOC1 2 (Ried & Eichhorn, 1988) ; 3,6-dichloropyridazine-4-carboxylic acid was available from 3,6-dichloro-4-methylpyridazine via oxidation with~Cr207 (Heinisch, 1973) . 3,6-Dichloro-N-(2-fluoro-5-methylphenyl)-pyridazine-4-carboxamide (3a) was prepared from 3,6dichloropyridazine-4-carboxylic acid chloride and 2-fluoroaniline (Heinisch et al., 1997a). 3,6-Dichloro-N-(2-fluoro-5-methylphenyl)-pyridazine-4-carboxamide (3b) To an ice-cooled solution of 2-fluoro-5-methylaniline (7.51 g, 60.00 mmol) in dry dichloromethane (70 mL) was added dropwise a solution of 3,6-dichloropyridazine-4carboxylic acid chloride (6.34 g, 30.00 mmol) in dry dichloromethane (30 mL) under a nitrogen atmosphere. The mixture was stirred at 4°C for 90 min and at room temperature for 1 h. The dichloromethane phase was extracted three times with 2 M NaOH, the aqueous solution was washed with dichloromethane and then acidified with concentrated HCl. The crystals which had separated were collected, washed with water and subsequently with light petroleum. An analytically pure sample was obtained upon recrystallization from ethyl acetate. Yield: 7.65 g (85%) of a light rose-coloured powder, Procedure for the synthesis of N-alkyl-3,6dichloro-N-(2-fluorophenyl)-pyridazine-4carboxamides (4) A mixture of 2-5 mmol of (substituted) 3,6-dichloro-N-(2-fluorophenyl)-pyridazine-4-carboxamide (3) and 4-10 mmol of powdered potassium hydroxide in dry dimethyl sulphoxide (15-30 mL) was stirred for 1 h under a nitrogen atmosphere. Then the appropriate alkyl iodide (1.5-2 Table 2 . N-Alkyl-3-alkylamino-6-chloro-N-(2-f1uorophenyIJ-pyridazine-4-carboxamides 5a-c, 6a-c, 7a-e and N-Alkyl-3-alkylamino-6-chloro-N-(2-f1uoro-5-methylphenyl)-pyridazine-4-carboxamides 5d-f, 6d-f and 7f-h. equiv.) was added and stirring continued until the starting material was completely consumed (TLC monitoring; diethyl ether or dichloromethane:ethyl acetate, 9:1). The reaction mixture was poured into cold 0.5 M HCl (100 mL) and the separated crystals were filtered off and washed with water and light petroleum. The filtrate was extracted with dichloromethane. The organic phase was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The products were purified by column chromatography (dichloromethane:ethyl acetate, 9:1) and recrystallization (diisopropyl ether). For yields and physical data see Table 1 .
General procedure for the synthesis of N-alkyl-
pyridazine-4-carboxamides (4) with ethylamine.To a solution of 2-5 mmol of the appropriate N-alkyl-3,6-dichloro-N-(2-fluorophenyl)-pyridazine-4-carboxamide (4) in 20-50 mL of dry l,4-dioxane were added 20-50 mmol (10 equiv.) of ethylamine hydrochloride and 20-50 mmol (10 equiv.) of sodium hydride (60% dispersion in oil). The reaction mixture was stirred under a nitrogen atmosphere (room temperature to 40°C) until the starting material was Antiviral Chemistry & Chematherapy 8 (4) completely consumed (TLC monitoring, diethyl ether). Then the reaction mixture was poured under a nitrogen atmosphere into 200-300 mL of cold 1 M HCl and the mixture was extracted with dichloromethane. The organic phase was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The products 5a-f thus obtained were purified by column chromatography and recrystallization. For yields, eluents, recrystallization solvents and physical data see Table 2 .
To a stirred solution or suspension of 0.5-4.0 mmol of the appropriate N-alkyl-3,6-dichloro-N-(2-fluorophenyl)-pyridazine-4-carboxamide (4) in dry l,4-dioxane (6 mL mmol") was added the amine (17-100 mmol) slowly at room temperature under nitrogen. The reaction mixture was stirred until TLC indicated no further conversion. Then the mixture was poured into 0.5 M HCl (around 100 mL mmol"), The crystals which had separated were filtered off, washed with water and light petroleum, and dried. The filtrate was extracted with dichloromethane and the organic layer was washed with water and brine, dried over sodium sulphate and evaporated. The residues thus obtained were purified by column chromatography and the combined products were recrys- tallized. For yields, eluents, recrystallization solvents and physical data see Table 2 .
General procedure far cyclizatian (i) Method A. 15-30 mmol of sodium hydride (60% dispersion in oil) was added at room temperature to a suspension of 1-2 mmol of the appropriate N-alkyl-3alkylamino-6-chloro-N-(2-fluorophenyl) -pyridazine-4carboxamide (5-7) in dry l,4-dioxane (30-60 mL) under an atmosphere of nitrogen, and the mixture was stirred under refluxed until TLC (diethyl ether) indicated no further conversion. Mter cooling to room temperature, the solution was poured under a nitrogen atmosphere into cold 0.5 M HCl (100-200 mL), the resulting crystals were collected, washed with water and subsequently with light petroleum, and dried in vacuo. If the product did not crystallize, the mixture was extracted with dichloromethane. The organic phase was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The products were purified by column chromatography and/ or recrystallization. For yields, eluents, recrystallization solvents and physical data see Table 3 .
(ii) Method B. 1-15 mmol of sodium hydride (60% dispersion in oil) were added at room temperature to a suspension of 0.2-5 mmol of the appropriate N-alkyl-3-alkylamino-6chloro-N-(2-fluorophenyl)-pyridazine-4-carboxamide 374 (5-7) in dry dimethyl formamide (5-30 mL) under an atmosphere of nitrogen, and the mixture was stirred at room temperature until TLC (diethyl ether or ethyl acetate: dichloromethane, 9:1) indicated no further conversion. The solution was poured under a nitrogen atmosphere into cold 0.5 M HCl (100-200 mL) and was extracted with diethyl ether. The organic phase was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The products were purified by column chromatography and/or recrystallization. For yields, eluents, recrystallization solvents and physical data see Table 3 .
Synthesis af 11-cyclapropyl-6, 11-dihydro-3-(1-imidazalyl)-6-methyl-5H-pyridazina[3,4-b] [1,5]benzadiazepin-5-ane (11)
To a solution of 0.2 mmol (60 mg) of lOa in 2.5 mL of dry dimethyl formamide was added 0.4 mmol of imidazole and 0.4 mmol of sodium hydride (60%). The mixture was stirred under a nitrogen atmosphere at 60°C for 5 h. Then the reaction mixture was poured in 20 mL of 0.5 M HCl and extracted with ethyl acetate (3x20 mL). The organic layer was extracted three times with 2 M HCl and the water phase was neutralized with saturated NaHC0 3 solution and then extracted with diethyl ether. The diethyl ether phase was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The solid thus obtained was purified by recrystallization from diisopropyl ether. , 6.49; N, 19.59; Found: C, 67.36; H, 6.20; N, 19.34. C Caled: C, 68.07; H, 6.85; N, 18.68; Found: C, 68.03; H, 6.50; N, .18.63. d Caled: C, 67.46; H, 7.21; N, 17.74; Found: C, 68.40; H, 7.09; N, 17.05. Yield: 47% (32 mg), m.p. 207-210"C; Cl8Hl6N60x0.5
Hp ( General procedure for dehq/ogenation A mixture of 1 mmol of the appropriate 3-chloro-8nitropyridazino [3,4-b] [1,5]benzodiazepin-5-one (8-10), 5 mmol of ammonium formate (0.315 g) and 0.114 g ofPd/C (10%) in 20 mL of methanol was stirred under a nitrogen atmosphere at 48°C for 30 min. The catalyst was filtered off, the solvent was removed in vacuo, and the residue was taken up in dichloromethane. This solution was washed with water and brine, dried over anhydrous sodium sulphate and evaporated. The products were purified by column chromatography and/or recrystallization. For yields,eluents, recrystallization solvents and physical data seeTable 4.
Materials and Experimental Procedures: Biology

HIV-l RT inhi/:,Jition
The measurement of in vitro HIV-1 RT inhibition was per-Antiviral Chemistry & Chemotherapy 8(4) formed with the non-radioactive RT-Kit from Boehringer Mannheim. For the exact composition and concentration of the solutions and for the precise working procedure see instructions of the assay (Cat. No. 1468 120) and Barth et al. (1996) . The compounds were dissolved in DMSO (20 mM) and further diluted with lysisbuffer shortly before use.
Results
Chemistry
The new pyridazino[3,4-b][1,5]benzodiazepin-5-ones 8-10 were synthesized in a multistep reaction sequence as outlined in Fig. 2 . The 3,6-dichloro-N-(2-fluorophenyl)pyridazine-4-carboxamides (3), easily obtained by acylation of 2-fluoroaniline or its 5-methyl derivative with 3,6-dichloropyridazine-4-carboxylic acid chloride, were N-alkylated using potassium hydroxide and an appropriate alkyl iodide. The corresponding 3-aminopyridazine-4-carboxamides 5-7 became accessible by exchange of the 3-chloro substituent by a primary aliphatic amine (ethylamine, propylamine and cyclopropylamine, respectively). Treatment of compounds 5-7 with an excess of sodium hydride in dry 1,4-dioxane or in dry dimethyl formamide, respectively, led to the new tricyclic compounds 8-10.
Since in the series of substituted pyridazino[3,4b][1,5]benzoxazepin-5(6H)-ones the 3-chloro derivatives turned out to exhibit only low inhibitory activity and to be pounds of type 8-10 into derivatives 12-14 could be only poorly soluble under the conditions required for achieved smoothly by catalytic transfer hydrogenation investigation of HIV-I RT inhibition (Barth et al., 1996) , employing ammonium formate as a hydrogen source. As the corresponding compounds 12-14 unsubstituted in exemplified in the preparation of 11, pyridazino[3,4position 3 were also prepared. Transformation of com-b][1,5]benzodiazepin-5-ones with a 3-(1-imidazolyl) sub- G Heinisch ef af. stituent could be obtained by reaction of a 3-chloro derivative with imidazole in the presence of sodium hydride in dry dimethyl formamide at 60T. Preparation of compound 11 was prompted by findings of Proudfoot et al. (1995) that azole or diazole substituents in the series of dipyridodiazepinones are beneficial for inhibitory activity against wild-type HIV-1 RT and Cys-181 HIV RT. All newly prepared compounds were fully characterized and their structures were assigned on the basis of microanalyses and IR and NMR spectra. A detailed presentation of the NMR data will be published elsewhere.
Virology
The new pyridazino [3,4-b] [1,5]benzodiazepin-5-ones of type 8-10, except those which were found not to be sufficiently soluble (Sa, 10f-h), were tested in vitro for inhibition of HIV-1 RT. Concentrations of 330 11M and 33 11M were used. The results obtained are summarized in Table 5 .
Discussion
Using a previously described synthetic strategy (Heinisch et al., 1997a) , a series of 6,1l-dialkylated 3-chloropyridazino-[3,4-b][1,5]benzodiazepin-5-ones bearing a hydrogen atom or a methyl group in position 8 was prepared.The 8-methyl substituted compounds were prepared since in the series of related pyridazino[3,4-b] [1,5]benzoxazepin-5(6H)-ones, methyl substitution of the carbocyclic aromatic moiety was found to increasethe inhibitory activity (Barth et al., 1996) . Further structural modifications of the new tricyclic compounds were performed by reductive dehalogenation or introduction of a 1-imidazolyl substituent into position 3.
The following structure-activity relationships could be established: in the series of 6,1l-dialkyl-3-chloro-6,11dihydro-5H-pyridazino[3,4-b][1,5]benzodiazepin-5-ones (2 with R2=CI and R3=H), the N(11)-cyclopropyl derivatives lOa and lOe were more potent than the related n-propyl congeners 9a and ge. However, in the case of compounds with an ethyl group in position 6 (9b, lOb), the N(ll)-cyclopropyl derivative was less potent. The N(l1)-ethyl derived compounds 8b and Se exhibited only very low potency; the 6-methyl derivative of this series (Sa) could not be tested owing to insufficient solubility.In the series of 6-alkyl-3-chloro-ll-cyclopropylpyridazino-[3,4-b][1,5]benzodiazepin-5-ones (lOa-e), the influence of the substituent in position 6 can be described as follows: the n-propyl derivative IDe was the most active compound, followed by N(6)-methyl (lOa), N(6)-allyl (IDe), N(6)-ethyl (lOb) and N(6)-butyl (lOd) substituted congeners. For the N(ll)-propyl substituted pyridazino- [3,4-b] [1,5]benzodiazepin-5-ones, the observed structure-activity relationships did not parallel that of the 378 N(l1)-cyclopropyl series: the 6-ethyl-ll-propyl derivative 9b was more active than the corresponding 6-methyl and 6-propyl congeners (9a and ge), which were equipotent.
The evaluation of the RT-inhibitory effect of halogenfree 6,1l-dialkylated pyridazino [3,4-b] [1,5]benzodiazepin-5-ones (2 with R2=R3=H) revealed that the substituent in position 11 had little effect on activity. These compounds were in general (except 13b, 14a and 14e) more potent than the corresponding 3-chloro substituted congeners. Introduction of a 3-(1-imidazolyl) substituent (11), however, led to a drastic decrease in inhibitory activity (compare activities of 11, lOa and 14a).
The 8-m<:thyl substituted 6-alkyl-3-chloro-ll-propylpyridazino[3,4-b][1,5]benzodiazepin-5-ones (2 with R2=CI and R3=8-CH 3) were in general significantlyless activethan the corresponding tricycles containing an unsubstituted carbocyclic moiety (compare activitiesof 9a-e versus 9d-f). In contrast, of compounds with an 11-ethyl substituent, the derivatives Sd and Se bearing a 8-methyl substituent were more active or better soluble than the corresponding compounds unsubstituted in the carbocyclic moiety (8b and Sc). In the series of the 3-chloro-8-methyl substituted compounds the ll-cyclopropyl substituted derivatives (lOf-h) turned out to be only poorly soluble under the conditions required for investigation of RT inhibition.
In the series of halogen-free 6,11-dialkyl-8-methylpyridazino[3,4-b][1,5]benzodiazepin-5-ones (2 with R2=H and R3=8-CH 3), the ll-ethyl derivatives (12d-f) turned out to be more potent than the ll-propyl (13d-f) and ll-cyclopropyl (14e-g) congeners.The influence of the substituent in position 6 can be described as follows: the ll-ethyl-6methyl and the 6,1l-diethyl substituted derivatives were equipotent whereas the corresponding 11-ethyl-6-propyl substituted compound exhibited lower potency.
In general, all new tricyclic compounds (S-14) were found to be less active than nevirapine (tested as the reference). Maximum enzyme inhibition in our series was obtained with the previously described compound 13a (Heinisch et al., 1997a,b) , with dehalogenated ll-ethyl-6,11-dihydro-5H-pyridazino[3,4-b] [1, 5] benzodiazepin-5-ones bearing a methyl or an ethyl group in position 6 (12a, 12b, 12d, 12e), and with the ll-cyclopropyl-6,11dihydro-6-propyl-5H-pyridazino[3,4-b] [1,5]benzodiazepin-5-ones IDe and 14e.
